E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma

Purpose: There is a paucity of biomarkers to predict failure in human papillomavirus–positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) following curative therapy. E6/E7 viral oncoproteins are constitutively expressed in HPV+ tumors and highly immunogenic, resulting in readily detected serum antibodies. The purpose of this study is to determine whether serum E6 and E7 antibody levels can potentially serve as a biomarker of recurrence in patients with HPV+OPSCC. Experimental Design: We evaluated E6/E7 antibody levels in patients with previously untreated, advanced stage (III, IVa-b), HPV+OPSCC receiving definitive chemoradiation under a uniform protocol from 2003 to 2010. Baseline and longitudinal serum samples were obtained from our archived repository. E6/E7 serum levels were measured using a glutathione-S-transferase capture ELISA and quantified by approximating the area under the dilution curve, and were analyzed using ANOVA and linear mixed model for longitudinal analysis. Results: We compared 22 HPV+OPSCC patients who developed recurrence with 30 patients who remained disease-free. There were no differences in T classification, N classification, disease subsite, or smoking status between the groups. In a longitudinal analysis, recurrent patients had significantly higher E6 and E7 serum antibody levels than the nonrecurrent patients over the follow-up period (P = 0.02 and P = 0.002, respectively). Patients who recurred had a lower clearance of E7 antibody than patients who remained disease-free (P = 0.0016). Conclusions: Patients with HPV+OPSCC whose disease recurs have a lower clearance of E6 and E7 antibodies than patients who do not have recurrence. The ratio of E7 antibody at disease recurrence compared with baseline is potentially a clinically significant measurement of disease status in HPV+OPSCC. Clin Cancer Res; 23(11); 2723–9. ©2016 AACR.

[1]  A. Eisbruch,et al.  Matted nodes as a predictor of distant metastasis in advanced‐stage III/IV oropharyngeal squamous cell carcinoma , 2016, Head & neck.

[2]  Daria A. Gaykalova,et al.  Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer , 2015, Cancer Prevention Research.

[3]  C. Chung,et al.  Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. , 2015, JAMA oncology.

[4]  Carole Fakhry,et al.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Qingyi Wei,et al.  HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. , 2015, Oral oncology.

[6]  K. Anderson,et al.  HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx , 2015, Clinical Cancer Research.

[7]  David J Sher,et al.  Human papillomavirus and head and neck cancer. , 2015, International journal of radiation oncology, biology, physics.

[8]  J. Califano,et al.  Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. , 2014, JAMA otolaryngology-- head & neck surgery.

[9]  E. Sturgis,et al.  Epidemiology of HPV-associated oropharyngeal cancer. , 2014, Oral oncology.

[10]  A. Eisbruch,et al.  High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. , 2013, JAMA otolaryngology-- head & neck surgery.

[11]  Wei Xu,et al.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Eisbruch,et al.  Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status , 2012, Head & neck.

[13]  S. McBride,et al.  Active tobacco smoking and distant metastasis in patients with oropharyngeal cancer. , 2012, International journal of radiation oncology, biology, physics.

[14]  Gypsyamber D'Souza,et al.  HPV-associated head and neck cancer: a virus-related cancer epidemic. , 2010, The Lancet. Oncology.

[15]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[16]  F. Feng,et al.  Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jens Overgaard,et al.  Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Westra,et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.

[20]  E. Sturgis,et al.  Trends in head and neck cancer incidence in relation to smoking prevalence , 2007, Cancer.

[21]  F. Feng,et al.  Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. , 2007, International journal of radiation oncology, biology, physics.

[22]  H. Wanebo,et al.  Changing patterns of failure of head and neck cancer. , 2002, Archives of otolaryngology--head & neck surgery.

[23]  M. Pawlita,et al.  A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. , 2001, Journal of immunological methods.